JPWO2015083374A1 - 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 - Google Patents
消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 Download PDFInfo
- Publication number
- JPWO2015083374A1 JPWO2015083374A1 JP2015551393A JP2015551393A JPWO2015083374A1 JP WO2015083374 A1 JPWO2015083374 A1 JP WO2015083374A1 JP 2015551393 A JP2015551393 A JP 2015551393A JP 2015551393 A JP2015551393 A JP 2015551393A JP WO2015083374 A1 JPWO2015083374 A1 JP WO2015083374A1
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- egg
- ostrich
- lipase
- egg yolk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000038379 digestive enzymes Human genes 0.000 title claims abstract description 25
- 108091007734 digestive enzymes Proteins 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 17
- 239000002994 raw material Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000000427 antigen Substances 0.000 claims abstract description 17
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 241000271566 Aves Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 241000272534 Struthio camelus Species 0.000 claims description 60
- 239000004367 Lipase Substances 0.000 claims description 35
- 102000004882 Lipase Human genes 0.000 claims description 15
- 108090001060 Lipase Proteins 0.000 claims description 15
- 235000019421 lipase Nutrition 0.000 claims description 15
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 7
- 108010059881 Lactase Proteins 0.000 claims description 7
- 241000271567 Struthioniformes Species 0.000 claims description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 7
- 102000016679 alpha-Glucosidases Human genes 0.000 claims description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 229940116108 lactase Drugs 0.000 claims description 7
- 239000004382 Amylase Substances 0.000 claims description 5
- 108010065511 Amylases Proteins 0.000 claims description 5
- 102000013142 Amylases Human genes 0.000 claims description 5
- 235000019418 amylase Nutrition 0.000 claims description 5
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 5
- 235000011073 invertase Nutrition 0.000 claims description 5
- 235000013601 eggs Nutrition 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 19
- 238000010521 absorption reaction Methods 0.000 abstract description 16
- 150000001720 carbohydrates Chemical class 0.000 abstract description 13
- 235000014633 carbohydrates Nutrition 0.000 abstract description 13
- 230000037406 food intake Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000015556 catabolic process Effects 0.000 abstract description 5
- 238000006731 degradation reaction Methods 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 206010020710 Hyperphagia Diseases 0.000 abstract description 2
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 235000020830 overeating Nutrition 0.000 abstract description 2
- 230000036186 satiety Effects 0.000 abstract description 2
- 235000019627 satiety Nutrition 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 102000002322 Egg Proteins Human genes 0.000 description 43
- 108010000912 Egg Proteins Proteins 0.000 description 43
- 210000002969 egg yolk Anatomy 0.000 description 43
- 235000013345 egg yolk Nutrition 0.000 description 40
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 34
- 229940040461 lipase Drugs 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 29
- 241000700159 Rattus Species 0.000 description 28
- 239000002285 corn oil Substances 0.000 description 24
- 235000005687 corn oil Nutrition 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 239000008103 glucose Substances 0.000 description 22
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 11
- 230000003053 immunization Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 235000019626 lipase activity Nutrition 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 102000019280 Pancreatic lipases Human genes 0.000 description 7
- 108050006759 Pancreatic lipases Proteins 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 229940116369 pancreatic lipase Drugs 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 241000286209 Phasianidae Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- 210000000969 egg white Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940040371 lecithin 10 mg Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/25—Addition or treatment with microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Description
成熟したメス鳥(ダチョウ、ニワトリ、ウズラ)を用いた。各抗原(リパーゼ、ラクターゼ、マルターゼ、サッカラーゼ、アミラーゼ)50μgをフロイントの完全アジュバント0.2mLと混和し、ダチョウに初回免疫した。各抗原を個別に5羽のダチョウ、5羽のニワトリ、5羽のウズラに接種した。ダチョウもニワトリもウズラも同量の抗原を接種したことになる。
各抗体が消化酵素に対する反応性を以下のようにして調べた。96穴ELISAプレートの各穴に各抗原(リパーゼ、ラクターゼ、マルターゼ、サッカラーゼ、アミラーゼ)10μgを別々に固層化した(室温で4時間)。その後、ダチョウ抗体(各3羽のダチョウから得た卵黄からの抗体の混合物)、ニワトリ抗体(各3羽のニワトリから得た卵黄からの抗体の混合物)、ウズラ抗体(各3羽のウズラから得た卵黄からの抗体の混合物)の段階希釈液(原液は2mg/mL)を各穴に滴下し、室温で1時間反応させた。
<膵リパーゼ活性に及ぼすダチョウ抗体(抗リパーゼ抗体)の阻害作用>
膵リパーゼ活性はトリオレインからのオレイン酸遊離量を測定することによって算出した。トリオレイン80mg(SIGMA)、レシチン10mg(和光純薬工業)、胆汁酸(SIGMA)を9mlの0.1Mトリス緩衝液(pH7.0)中で10分間超音波処理を行うことで均一な懸濁液とし、これを基質液として用いた。
使用したダチョウ卵黄は、リパーゼを免疫したダチョウの卵(初回免疫後8週目)からの卵黄(生)である。ラットを1群6匹として対照群(control)、ダチョウ卵黄投与群(10,100,1000mg/匹)の4群に分け、一晩絶食し、コーンオイル負荷実験を行った。対照群ではコーンオイルエマルジョン1ml及び免疫前卵黄1000mgの混合液を非麻酔科でラットに経口投与した。
使用したダチョウ卵黄は、リパーゼを免疫したダチョウの卵(初回免疫後8週目)からの卵黄(生)を加熱処理(120℃10分)したものである。ラットを1群6匹として対照群(control)、加熱処理ダチョウ卵黄投与群(10,100,1000mg/匹)の4群に分け、一晩絶食し、コーンオイル負荷実験を行った。対照群ではコーンオイルエマルジョン1ml及び免疫前卵黄1000mgの混合液を非麻酔科でラットに経口投与した。
若齢および老齢マウスに高脂肪食およびダチョウ卵黄抗体液(抗リパーゼ抗体)(飲水に添加)を自由摂取させ、経時的に体重を測定した。より具体的に各グループは、若齢マウスで抗リパーゼ抗体を摂取させたグループ(6匹)、若齢マウスで抗リパーゼ抗体を摂取させなかったグループ(6匹)、老齢マウスで抗リパーゼ抗体を摂取させたグループ(6匹)、老齢マウスで抗リパーゼ抗体を摂取させなかったグループ(6匹)である。
Claims (6)
- 消化酵素を抗原としてダチョウの雌に接種する工程と、
前記ダチョウの雌が産卵した卵から抗体を精製する工程を含むことを特徴とする消化酵素抗体の製造方法。 - 前記抗原は、リパーゼ、ラクターゼ、マルターゼ、サッカラーゼ、アミラーゼのうち少なくとも1つを含むことを特徴とする請求項1に記載された消化酵素抗体の製造方法。
- 請求項1または2のいずれかの方法で製造された抗体を原料とする組成物であって、前記抗体が消化酵素と結合することを特徴とする組成物。
- 消化酵素を抗原として鳥類の雌に接種し、前記鳥類の雌が産んだことを特徴とする卵。
- 前記鳥類がダチョウであることを特徴とする請求項1に記載された卵。
- 請求項4または5に記載の前記卵を原料とする加工品。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013249673 | 2013-12-02 | ||
JP2013249673 | 2013-12-02 | ||
JP2014169649 | 2014-08-22 | ||
JP2014169649 | 2014-08-22 | ||
PCT/JP2014/006027 WO2015083374A1 (ja) | 2013-12-02 | 2014-12-02 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019146548A Division JP2019199480A (ja) | 2013-12-02 | 2019-08-08 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2015083374A1 true JPWO2015083374A1 (ja) | 2017-03-16 |
JP6778488B2 JP6778488B2 (ja) | 2020-11-04 |
Family
ID=53273157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015551393A Active JP6778488B2 (ja) | 2013-12-02 | 2014-12-02 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
JP2019146548A Pending JP2019199480A (ja) | 2013-12-02 | 2019-08-08 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019146548A Pending JP2019199480A (ja) | 2013-12-02 | 2019-08-08 | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10053516B2 (ja) |
JP (2) | JP6778488B2 (ja) |
WO (1) | WO2015083374A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10538593B2 (en) | 2013-12-02 | 2020-01-21 | Ostrich Pharma Kk | Method for manufacturing digestive enzyme antibody and egg having same, and for manufacturing processed product containing egg as ingredient thereof and composition including antibody |
JP6872841B2 (ja) * | 2014-04-28 | 2021-05-19 | アサマ化成株式会社 | 脂肪低減組成物 |
WO2019087372A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001521900A (ja) * | 1997-10-31 | 2001-11-13 | シューズッカー アクチエンゲセルシャフト | 高血糖症の治療のための二糖誘導体 |
KR20030026046A (ko) * | 2001-09-24 | 2003-03-31 | (주)바이오랩 | 수크라아제와 말타아제에 대한 난황항체의 생산방법 및이를 이용한 식이 탄수화물의 흡수 억제용 조성물 |
KR20030079382A (ko) * | 2002-04-04 | 2003-10-10 | 최태부 | 소화 효소-지방산 복합체를 항원으로하여 생산된 항체 및이의 이용 |
WO2004089386A1 (ja) * | 2003-04-10 | 2004-10-21 | Ghen Corporation | 消化酵素に対する鶏卵抗体を用いた抗肥満剤 |
WO2007026689A1 (ja) * | 2005-08-29 | 2007-03-08 | Japan Science And Technology Agency | ダチョウを用いた抗体、及びその作製方法 |
JP2012224589A (ja) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | 糖質吸収抑制物質 |
JP2013147471A (ja) * | 2012-01-23 | 2013-08-01 | Venture Bank Inc | ダチョウ抗体水溶液 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3658460B2 (ja) * | 1996-05-27 | 2005-06-08 | 日本製粉株式会社 | 食品、食品の保存方法及び食品保存剤 |
US7344713B1 (en) * | 1997-07-07 | 2008-03-18 | Pimentel Julio L | Decreased fat absorption with an anti-lipase antibody |
WO2010041343A1 (ja) | 2008-10-07 | 2010-04-15 | 株式会社エコビジネス | 穀物等に味わい性を向上したグァバ葉抽出濃縮エキスを混合させた健康食品 |
JP2011020927A (ja) * | 2009-07-13 | 2011-02-03 | Ostrich Pharma Kk | ダチョウ産生による抗体およびそれを用いたフィルター |
JP2012211084A (ja) | 2009-07-17 | 2012-11-01 | Amano Enzyme Inc | 酵素組成物 |
-
2014
- 2014-12-02 US US15/100,821 patent/US10053516B2/en active Active
- 2014-12-02 WO PCT/JP2014/006027 patent/WO2015083374A1/ja active Application Filing
- 2014-12-02 JP JP2015551393A patent/JP6778488B2/ja active Active
-
2019
- 2019-08-08 JP JP2019146548A patent/JP2019199480A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001521900A (ja) * | 1997-10-31 | 2001-11-13 | シューズッカー アクチエンゲセルシャフト | 高血糖症の治療のための二糖誘導体 |
KR20030026046A (ko) * | 2001-09-24 | 2003-03-31 | (주)바이오랩 | 수크라아제와 말타아제에 대한 난황항체의 생산방법 및이를 이용한 식이 탄수화물의 흡수 억제용 조성물 |
KR20030079382A (ko) * | 2002-04-04 | 2003-10-10 | 최태부 | 소화 효소-지방산 복합체를 항원으로하여 생산된 항체 및이의 이용 |
WO2004089386A1 (ja) * | 2003-04-10 | 2004-10-21 | Ghen Corporation | 消化酵素に対する鶏卵抗体を用いた抗肥満剤 |
WO2007026689A1 (ja) * | 2005-08-29 | 2007-03-08 | Japan Science And Technology Agency | ダチョウを用いた抗体、及びその作製方法 |
JP2012224589A (ja) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | 糖質吸収抑制物質 |
JP2013147471A (ja) * | 2012-01-23 | 2013-08-01 | Venture Bank Inc | ダチョウ抗体水溶液 |
Non-Patent Citations (1)
Title |
---|
"新規抗リパーゼ鶏卵抗体による抗肥満作用", 日本栄養・食糧学会大会講演要旨集, vol. Vol.66th Page.127, JPN6018041037, 27 April 2014 (2014-04-27), ISSN: 0004116888 * |
Also Published As
Publication number | Publication date |
---|---|
US20160304623A1 (en) | 2016-10-20 |
WO2015083374A1 (ja) | 2015-06-11 |
JP6778488B2 (ja) | 2020-11-04 |
US10053516B2 (en) | 2018-08-21 |
JP2019199480A (ja) | 2019-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019199480A (ja) | 消化酵素抗体およびそれを有する卵と卵を原料とする加工品および抗体を含む組成物と製造方法 | |
Gujral et al. | Effect of anti-gliadin IgY antibody on epithelial intestinal integrity and inflammatory response induced by gliadin | |
Shane | Mannan oligosaccharides in poultry nutrition: mechanisms and benefits. | |
JP2008044945A (ja) | 感染症に対抗する代替医薬品としてのプロバイオティクス | |
Al-Baadani et al. | The use of gum Arabic as a natural prebiotic in animals: A review | |
JP7495985B2 (ja) | ペットフード組成物 | |
Donma et al. | Beneficial effects of poultry meat consumption on cardiovascular health and the prevention of childhood obesity | |
Gong et al. | Effects of laying breeder hens dietary β-carotene, curcumin, allicin, and sodium butyrate supplementation on the growth performance, immunity, and jejunum morphology of their offspring chicks | |
Zhao et al. | Food chemistry of selenium and controversial roles of selenium in affecting blood cholesterol concentrations | |
JP2011050347A (ja) | α−リノレン酸強化卵及びその用途 | |
WO2016136624A1 (ja) | 免疫調節剤及びその用途 | |
JP2986324B2 (ja) | ダイエット・糖尿病用食品 | |
Campbell-McBride | Gut and psychology syndrome | |
US10538593B2 (en) | Method for manufacturing digestive enzyme antibody and egg having same, and for manufacturing processed product containing egg as ingredient thereof and composition including antibody | |
Van Arsdall et al. | Is there a role for the enteral administration of serum-derived immunoglobulins in human gastrointestinal disease and pediatric critical care nutrition? | |
Qui et al. | Effects of dietary β-glucan and rice fermented on growth performance, fatty acids, and Newcastle disease immune response in turkey broilers | |
Bryan et al. | The influence of indigestible protein on broiler digestive tract morphology and caecal protein fermentation metabolites | |
CN106573034B (zh) | 海洋肽和鱼核苷酸、组合物及其用于降低血糖的用途 | |
WO2016072507A1 (ja) | 消化性潰瘍の予防又は治療剤,及び予防又は治療のための食品添加物,iNOS発現抑制剤及びCOX-2発現抑制剤 | |
Rama Rao et al. | Utilization of graded levels of finger millet (Eleusine coracana) in place of yellow maize in commercial broiler chicken diets | |
JP6476043B2 (ja) | 消化性潰瘍の予防又は治療剤,及び予防又は治療のための食品添加物 | |
US20180071237A1 (en) | Treatment method for improving intestinal enviornment and intestinal tract barrier | |
KR20100090441A (ko) | 비만과 고지혈증 예방 및 치료를 위한 특이 난황항체를 포함하는 조성물 | |
JP7075671B2 (ja) | 細菌感染症用ダチョウ抗体 | |
RU2005383C1 (ru) | Способ снижения холестерина в пищевом продукте |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171124 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181213 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190808 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190808 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190820 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190821 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190913 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190918 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200603 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20200831 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20200929 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20200929 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201012 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6778488 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |